covishield Search Results


covishield  (AstraZeneca ltd)
90
AstraZeneca ltd covishield
Demographic data of included participants without breakthrough infection.
Covishield, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covishield/covishield/pmc08727751-30-7-1
Average 90 stars, based on 1 article reviews
covishield - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
vacunas covid-19 astrazeneca/covishield  (AstraZeneca ltd)
90
AstraZeneca ltd vacunas covid-19 astrazeneca/covishield
Demographic data of included participants without breakthrough infection.
Vacunas Covid 19 Astrazeneca/Covishield, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covishield/vacunas+covid+19+astrazeneca+covishield/pmc11110664-44-12-13
Average 90 stars, based on 1 article reviews
vacunas covid-19 astrazeneca/covishield - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
sii/covishield  (AstraZeneca ltd)
90
AstraZeneca ltd sii/covishield
Demographic data of included participants without breakthrough infection.
Sii/Covishield, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covishield/sii+covishield/10__1016_slash_j__arabjc__2021__103240-30-5-7
Average 90 stars, based on 1 article reviews
sii/covishield - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
covishield/astrazeneca vaccinated sera  (AstraZeneca ltd)
90
AstraZeneca ltd covishield/astrazeneca vaccinated sera
Demographic data of included participants without breakthrough infection.
Covishield/Astrazeneca Vaccinated Sera, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covishield/covishield+astrazeneca+vaccinated+sera/pmc08472862-75-9-9
Average 90 stars, based on 1 article reviews
covishield/astrazeneca vaccinated sera - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
az/covishield  (AstraZeneca ltd)
90
AstraZeneca ltd az/covishield
Demographic data of included participants without breakthrough infection.
Az/Covishield, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covishield/az+covishield/ppr0385975-20-20-19
Average 90 stars, based on 1 article reviews
az/covishield - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
oxford/astrazeneca covid-19 vaccine covishield  (AstraZeneca ltd)
90
AstraZeneca ltd oxford/astrazeneca covid-19 vaccine covishield
Examples of Commercially Available Treatment for Respiratory Viral Infections
Oxford/Astrazeneca Covid 19 Vaccine Covishield, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covishield/covid+19+vaccine+covishield/pmc10129308-15-2-1
Average 90 stars, based on 1 article reviews
oxford/astrazeneca covid-19 vaccine covishield - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
az/covishield  (Sinopharm ltd)
90
Sinopharm ltd az/covishield
Examples of Commercially Available Treatment for Respiratory Viral Infections
Az/Covishield, supplied by Sinopharm ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covishield/covishield/pmc10923657-23-32-41
Average 90 stars, based on 1 article reviews
az/covishield - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
oxford/covishield  (AstraZeneca ltd)
90
AstraZeneca ltd oxford/covishield
Examples of Commercially Available Treatment for Respiratory Viral Infections
Oxford/Covishield, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covishield/oxford+covishield/pmc11198793-129-22-23
Average 90 stars, based on 1 article reviews
oxford/covishield - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
indian covishield  (AstraZeneca ltd)
90
AstraZeneca ltd indian covishield
Examples of Commercially Available Treatment for Respiratory Viral Infections
Indian Covishield, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covishield/indian+covishield/pmc12060757-48-14-16
Average 90 stars, based on 1 article reviews
indian covishield - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
one million doses of astrazeneca (covishield)  (AstraZeneca ltd)
90
AstraZeneca ltd one million doses of astrazeneca (covishield)
Examples of Commercially Available Treatment for Respiratory Viral Infections
One Million Doses Of Astrazeneca (Covishield), supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covishield/one+million+doses+of+astrazeneca++covishield+/pmc10129202-119-20-20
Average 90 stars, based on 1 article reviews
one million doses of astrazeneca (covishield) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
covishield candidate vaccine  (AstraZeneca ltd)
90
AstraZeneca ltd covishield candidate vaccine
Examples of Commercially Available Treatment for Respiratory Viral Infections
Covishield Candidate Vaccine, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covishield/recombinant++covishield++vaccine/pmc08374532-198-20-37
Average 90 stars, based on 1 article reviews
covishield candidate vaccine - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
covishield (oxford astrazeneca chimpanzee adenovirus-based vectored vaccine)  (AstraZeneca ltd)
90
AstraZeneca ltd covishield (oxford astrazeneca chimpanzee adenovirus-based vectored vaccine)
Characteristics of patients who developed cutaneous manifestations post‐COVID‐19 vaccination
Covishield (Oxford Astrazeneca Chimpanzee Adenovirus Based Vectored Vaccine), supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covishield/covishield++oxford+astrazeneca+chimpanzee+adenovirus+based+vectored+vaccine+/pmc08662281-22-15-17
Average 90 stars, based on 1 article reviews
covishield (oxford astrazeneca chimpanzee adenovirus-based vectored vaccine) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Demographic data of included participants without breakthrough infection.

Journal: Frontiers in Medicine

Article Title: Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines

doi: 10.3389/fmed.2021.778129

Figure Lengend Snippet: Demographic data of included participants without breakthrough infection.

Article Snippet: The AstraZeneca US Phase III trial of Covishield demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization ( ).

Techniques: Infection

Levels of antibody against spike (S) glycoprotein at different timepoints after a complete dose of Covishield and Covaxin recipient without any breakthrough infection (A) . Anti-S antibody levels of Covishield recipients stratified by gender (B) , age (C) , and comorbidities (D) . “ns” indicates nonsignificant; * indicates p < 0.05; ** indicates p < 0.01; *** indicates p < 0.001. The Tukey's method was used to plot whiskers.

Journal: Frontiers in Medicine

Article Title: Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines

doi: 10.3389/fmed.2021.778129

Figure Lengend Snippet: Levels of antibody against spike (S) glycoprotein at different timepoints after a complete dose of Covishield and Covaxin recipient without any breakthrough infection (A) . Anti-S antibody levels of Covishield recipients stratified by gender (B) , age (C) , and comorbidities (D) . “ns” indicates nonsignificant; * indicates p < 0.05; ** indicates p < 0.01; *** indicates p < 0.001. The Tukey's method was used to plot whiskers.

Article Snippet: The AstraZeneca US Phase III trial of Covishield demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization ( ).

Techniques: Infection

Anti-S immunoglobulin G (IgG) antibody levels at different timepoints of the Covishield and Covaxin vaccine recipients having breakthrough infection (A) . The symptomatic status with percentage of all the breakthrough cases (B) . The Tukey's method was used to plot whiskers.

Journal: Frontiers in Medicine

Article Title: Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines

doi: 10.3389/fmed.2021.778129

Figure Lengend Snippet: Anti-S immunoglobulin G (IgG) antibody levels at different timepoints of the Covishield and Covaxin vaccine recipients having breakthrough infection (A) . The symptomatic status with percentage of all the breakthrough cases (B) . The Tukey's method was used to plot whiskers.

Article Snippet: The AstraZeneca US Phase III trial of Covishield demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization ( ).

Techniques: Infection

Examples of Commercially Available Treatment for Respiratory Viral Infections

Journal: Pharmaceutical Research

Article Title: Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections

doi: 10.1007/s11095-023-03520-1

Figure Lengend Snippet: Examples of Commercially Available Treatment for Respiratory Viral Infections

Article Snippet: , Oxford/AstraZeneca Covid-19 vaccine (Covishield and Vaxzevria) , Intramuscular , .

Techniques: Infection

Characteristics of patients who developed cutaneous manifestations post‐COVID‐19 vaccination

Journal: Journal of Cosmetic Dermatology

Article Title: Benign cutaneous reactions post‐COVID‐19 vaccination: A case series of 16 patients from a tertiary care center in India

doi: 10.1111/jocd.14592

Figure Lengend Snippet: Characteristics of patients who developed cutaneous manifestations post‐COVID‐19 vaccination

Article Snippet: We intend to report the first series of cutaneous side effects noted with two vaccines, Covishield (Oxford AstraZeneca chimpanzee adenovirus‐based vectored vaccine) and Covaxin (inactivated COVID‐19 vaccine), from a tertiary care Centre in Eastern India.

Techniques: Injection

Cutaneous manifestations following Covishield (OXFORD ASTRAZENECA) vaccine. (A) Multiple grouped vesicles of Herpes zoster along the left C5 dermatome 2 days after Covishield vaccine. (B) Multiple wheals on the back of patient 1 day after Covishield vaccine. (C) Injection site erythema with pruritus 1 day after Covishield vaccine

Journal: Journal of Cosmetic Dermatology

Article Title: Benign cutaneous reactions post‐COVID‐19 vaccination: A case series of 16 patients from a tertiary care center in India

doi: 10.1111/jocd.14592

Figure Lengend Snippet: Cutaneous manifestations following Covishield (OXFORD ASTRAZENECA) vaccine. (A) Multiple grouped vesicles of Herpes zoster along the left C5 dermatome 2 days after Covishield vaccine. (B) Multiple wheals on the back of patient 1 day after Covishield vaccine. (C) Injection site erythema with pruritus 1 day after Covishield vaccine

Article Snippet: We intend to report the first series of cutaneous side effects noted with two vaccines, Covishield (Oxford AstraZeneca chimpanzee adenovirus‐based vectored vaccine) and Covaxin (inactivated COVID‐19 vaccine), from a tertiary care Centre in Eastern India.

Techniques: Injection